These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 1514204)

  • 21. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical treatment options in patients with metastatic renal cell carcinoma.
    Haferkamp A; Hohenfellner M
    Nephrol Dial Transplant; 2007 Apr; 22(4):996-9. PubMed ID: 17210591
    [No Abstract]   [Full Text] [Related]  

  • 23. [Problems in the therapy of kidney neoplasms].
    Masuda F
    Nihon Hinyokika Gakkai Zasshi; 1985 Nov; 76(11):1612-8. PubMed ID: 3835352
    [No Abstract]   [Full Text] [Related]  

  • 24. [Prognostic factors for predicting the success of immunotherapy in metastatic renal cell carcinoma].
    Schmitz-Dräger BJ; Jankevicius F; Otto T
    Urologe A; 1995 May; 34(3):195-9. PubMed ID: 7610511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
    Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
    Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
    Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Update on the medical treatment of urologic tumors].
    Culine S
    Bull Cancer; 2000 Jan; 87(1):71-5. PubMed ID: 10673634
    [No Abstract]   [Full Text] [Related]  

  • 29. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
    Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Adenocarcinoma of the kidney (hypernephroma)].
    Probst W; Joss R; Triller J; Schönenberger A; Greiner R; Brunner KW
    Schweiz Med Wochenschr; 1984 Oct; 114(41):1406-15. PubMed ID: 6208605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
    Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
    J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
    Pantuck AJ; Belldegrun AS; Figlin RA
    N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunotherapy for metastatic renal cell carcinoma.
    Wirth MP
    Urol Clin North Am; 1993 May; 20(2):283-95. PubMed ID: 7684167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant alpha-2 or gamma interferon in the treatment of metastatic renal cell carcinoma: results of two phase II/III trials.
    Otto U; Schneider AW; Conrad S; Klosterhalfen H
    Prog Clin Biol Res; 1990; 350():275-82. PubMed ID: 2117287
    [No Abstract]   [Full Text] [Related]  

  • 36. [Long-term results in the treatment of 100 metastatic hypernephroid carcinomas].
    Falk W; Halama JM; Halama J
    Strahlenther Onkol; 1990 Apr; 166(4):256-64. PubMed ID: 2139518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
    Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
    J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter phase II study of chemo-immunotherapy in the treatment of metastatic renal cell carcinoma.
    Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Necozione S; Fumagalli L; Rea S
    J Immunother; 2007; 30(4):448-54. PubMed ID: 17457219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant interferon alpha therapy in renal cell carcinoma (RCC): prognostic value of DNA cytophotometry.
    Basting R; Corvin S; Händel D; Hinke A; Schmidt D
    Anticancer Res; 1999; 19(2C):1493-5. PubMed ID: 10365130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The combined therapy of intervention, operation and biology in patients with middle-advanced renal cell carcinoma].
    Song XS; He ZZ; Yin JB; Zhang RK; Che XY; Wang JB
    Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1450-2. PubMed ID: 15733463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.